BioSyent Inc. (TSXV: RX)

Market Cap	131.01M
Revenue (ttm)	34.51M
Net Income (ttm)	7.11M
Shares Out	11.59M
EPS (ttm)	0.60
PE Ratio	18.88
Forward PE	16.62
Dividend	0.18 (1.65%)
Ex-Dividend Date	Sep 4, 2024

Volume	30,477
Open	10.99
Previous Close	10.91
Day's Range	10.99 - 11.30
52-Week Range	8.20 - 11.49
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2023, BioSyent's revenue was 31.59 million, an increase of 13.12% compared to the previous year's 27.93 million. Earnings were 6.46 million, an increase of 18.35%.